Cullinan Therapeutics, Inc. (CGEM) Earnings Call Transcripts
Cullinan Therapeutics, Inc.'s Latest Earnings Call - June 10, 2026
Cullinan Therapeutics reported its Q2 2026 earnings, highlighting significant advancements in its immunology pipeline, particularly with its T-cell engagers CLN-978 and velinotamig. The company presented promising data at EULAR, showcasing potential breakthroughs in treating autoimmune diseases. Revenue and earnings specifics were not disclosed, but the focus was on clinical data and pipeline progress. Management did not provide explicit financial guidance but emphasized upcoming catalysts and regulatory pathways.
Reported metrics
| Metric | Value |
|---|---|
| Patient Treatment | 42 patients treated with CLN-978 (positive) |
| CRS Incidence | 40% (inline) |
| B-cell Depletion | Complete in tissue (positive) |
| Velinotamig Dose | 10 micrograms/kg (positive) |
Guidance from management
Management indicated plans to initiate Phase IIa studies for CLN-978 in early 2027, with potential accelerated approval pathways for lupus nephritis.
What management said
No, that's certainly a wealth of experience that we benefited from and will continue to benefit from as our research partnership continues. And I think maybe before we talk about what's new in SLE. Maybe you could talk a little bit about the typical patient journey. So what do you do for patients with SLE? How do you characterize the unmet need? Because if we're going to solve a problem, we actually need to know what...
Yes. And so understanding the challenge in getting patients to remission is there an ability to get patients. So they've started first with Plaquenil, steroids, you try to get them off hopefully with immune suppressants or one of these advanced biologics. Do you have the ability today to put a patient into remission such that they stop everything.
What analysts pressed on
Analysts questioned the therapeutic index for CLN-978, particularly in light of a Grade 3 CRS incident at a higher dose. There were also inquiries about the comparability of data from China-based studies for velinotamig.
Main topics on the call
- Promising Clinical Data — Management highlighted that the data for CLN-978 'exceeded our expectations' with significant efficacy in autoimmune diseases, including RA and SLE. The data showed potential for immune reset and disease modification.
- Pipeline Strategy — Cullinan is advancing a broad pipeline of T-cell engagers targeting CD19 and BCMA, aiming to deliver best-in-class disease-modifying medicines. The strategy includes both immunology and oncology applications.
- Regulatory Pathways — Management discussed potential expedited regulatory pathways, including accelerated approval for lupus nephritis based on monotherapy efficacy signals.
- Safety Profile — The safety profile of CLN-978 was described as favorable, with manageable CRS incidents. Velinotamig showed an exceptional safety profile with no CRS or ICANs in initial studies.
Read the full Cullinan Therapeutics, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. (CGEM) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 20 calls on record spanning June 4, 2021 to June 10, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 20 Cullinan Therapeutics, Inc. earnings call transcripts on record, spanning June 4, 2021 to June 10, 2026. Based on this history, Cullinan Therapeutics, Inc. reports quarterly. The most recent call on file is dated June 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- CGEM
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 20
- First call
- June 4, 2021
- Most recent
- June 10, 2026
- Reporting cadence
- quarterly